DCCT, Diabetes Control and Complications Trial; IDDM, insulin-dependent diabetes mellitus; ESRD, end-stage renal disease; DM, diabetes mellitus; QALY, quality-adjusted life year; IC-ER, incremental cost-effectiveness ratio; ACE, angiotensin-converting enzyme; CVD, cardiovascular disease; ATDs, antithyroid drugs; FNA, fine-needle aspiration; PRL, prolactin; MRI, magnetic resonance imaging; QALE, quality-adjusted life expectancy.
• DCCT. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial The Diabetes Control and Complications Trial Research Group. JAMA. 1996;276(17):1409-1415.
• The CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA. 1998;280(20):1757-1763.
• Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med. 1997;127(9):788-795.
• Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med. 2004;140(9):689-699.
• Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ. 2008;336:1180-1185.
• Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med.1999;131(9):660-667.
• Gaede P, Valentine WJ, Palmer AJ, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes. Diabetes Care. 2008;31(8):1510-1515.
• Danese MD, Powe NR, Sawin CT, Ladenson PW. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. JAMA.1996;276(4):285-292.
• Vidal-Trecan GM, Stahl JE, Durand-Zaleski I. Managing toxic thyroid adenoma: a cost-effectiveness analysis. Eur J Endocrinol. 2002;146(3):283-294.
• Nasuti JF, Gupta PK, Baloch ZW. Diagnostic value and cost-effectiveness of on-site evaluation of fine-needle aspiration specimens: review of 5,688 cases. Diagn Cytopathol.2002;27(1):1-4.
• McCartney CR, Stukerborg GJ. Decision analysis of discordant thyroid nodule biopsy guideline criteria. J Clin Endocrinol Metab. 2008;93(8):3037-3044.
• Cheung K, Roman SA, Wang TS, Walker HD, Sosa JA. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. J Clin Endocrinol Metab. 2008;93(6):2173-2180.
• King JT, Jr, Justice AC, Aron DC. Management of incidental pituitary microadenomas: a cost-effectiveness analysis. J Clin Endocrinol Metab. 1997;82(11):3625-3632.
• Sawka AM, Gafni A, Thabane L, Young WF, Jr. The economic implications of three biochemical screening algorithms for pheochromocytoma. J Clin Endocrinol Metab.2004;89(6):2859-2866.
• Col NF, Weber G, Stiggelbout A, Chuo J, D'Agostino R, Corso P. Short-term menopausal hormone therapy for symptom relief: an updated decision model. Arch Intern Med.2004;164(15):1634-1640.
• Smith KJ, Roberts MS. The cost-effectiveness of sildenafil. Ann Intern Med. 2000;132(12):933-937.